MBX Biosciences assumed with a Buy at Jefferies

Jefferies assumed coverage of MBX Biosciences (MBX) with a Buy rating and $36 price target The firm believes that if canvuparatide can show a 50%-60% response and favorable safety in the upcoming Phase 2 readout, the stock could see 50%-100% upside potential. In this case MBX could move into Phase 3 with a competitive profile and capture “decent” future hypoparathyroidism market share, the analyst tells investors in a research note.